{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-022931","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.103250+00:00","generated_at":"2026-05-15T07:52:17.083411+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer","bullets":["FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.","Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.","Interim data from the Phase 1a trial expected in June 2026.","Fast Track aims to expedite development and review for serious conditions with unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-022931","json":"https://secwatch.observer/filing/0001628280-26-022931.json","markdown":"https://secwatch.observer/filing/0001628280-26-022931.md","text":"https://secwatch.observer/filing/0001628280-26-022931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/0001628280-26-022931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/cntx-20260402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:52:17.083411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}